Jefferies still bullish on Opko despite short call


Jefferies is out with some commentary on Opko Health (OPK +5.2%) amid controversy surrounding a short thesis advanced by Lakewood Capital (see Lakewood's article on SA here).

"In our view, timely achievements of its laid-out milestones and future sales revenues meeting our expectations (albeit significantly lower than its noted market opportunities) would likely provide potential upside to current levels," analyst Eun Yang says.

Buy rating reiterated.

Price target is $11.50.

From other sites
Comments (4)
  • Qniform
    , contributor
    Comments (4566) | Send Message
     
    What an annoying site at that embedded link for commentary. I hate those mouse cursor pop-ups...
    18 Dec 2013, 12:23 PM Reply Like
  • phredwelll
    , contributor
    Comments (6) | Send Message
     
    I think opko shares are being bought by chairman Frost for family rather than for himself. Opko will be at $36.00 by mid 2014.
    18 Dec 2013, 12:44 PM Reply Like
  • Kf919hk
    , contributor
    Comment (1) | Send Message
     
    What make you the stock would go that high?
    9 Feb 2014, 12:31 PM Reply Like
  • Spuzdude
    , contributor
    Comments (9) | Send Message
     
    Agree. The Doctor is way ahead of these short sellers.
    18 Dec 2013, 03:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs